In contrast to the two previously mentioned studies, in a phase 2 trial, no confirmed responses were observed with veliparib an oral PARP inhibitor, in individuals with treatment refractory BRCA1/2 or PALB2 mutant pancreatic adenocarcinoma [33]. The gene discussed is BRCA1; the disease is pancreatic adenocarcinoma.